The Aliskiren Trial to Minimize OutcomeS in Patients with HEart failure trial (ATMOSPHERE): Revised statistical analysis plan and baseline characteristics

European Journal of Heart Failure

Volumn 17, Issue 10, 2015, Pages 1075-1083

  Krum, Henry ^a   McMurray, John J V ^b   Abraham, William T ^c   Dickstein, Kenneth ^d   Køber, Lars ^e   Desai, Akshay S ^f   Solomon, Scott D ^f   Chiang, Yanntong ^g   Gimpelewicz, Claudio ^g   Reimund, Bernard ^g   Ali, M Atif ^g   Tarnesby, Georgia ^g   Massie, Barry M ^h  

^a MONASH UNIVERSITY   (Australia)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c OHIO STATE UNIVERSITY   (United States)

^d STAVANGER UNIVERSITY HOSPITAL   (Norway)

^e Rigshospitalet   (Denmark)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

^g NOVARTIS PHARMA AG   (Switzerland)

^h UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Aliskiren; Characteristics; Heart failure

Indexed keywords

ACETYLSALICYLIC ACID; ALISKIREN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; MINERALOCORTICOID ANTAGONIST; RENIN INHIBITOR; SACUBITRIL PLUS VALSARTAN; AMIDE; CARDIOVASCULAR AGENT; FUMARIC ACID DERIVATIVE; RENIN;

ADULT; ARTICLE; BODY MASS; CLINICAL FEATURE; COMORBIDITY; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC PATIENT; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG MEGADOSE; FEMALE; GLOMERULUS FILTRATION RATE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; PARALLEL DESIGN; PATIENT CARE PLANNING; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS; ANTAGONISTS AND INHIBITORS; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; HEART LEFT VENTRICLE FUNCTION; HEART STROKE VOLUME; MIDDLE AGED;

AMIDES; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CARDIOVASCULAR AGENTS; DIABETES MELLITUS; DRUG THERAPY, COMBINATION; ENALAPRIL; FEMALE; FUMARATES; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; RENIN; STROKE VOLUME; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84945935418     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1002/ejhf.408     Document Type: Article

References (16)

1. Krum H, Massie B, Abraham WT, Dickstein K, Kober L, McMurray JJ, Desai A, Gimpelewicz C, Kandra A, Reimund B, Rattunde H, Armbrecht J,; ATMOSPHERE Investigators. Direct renin inhibition in addition to or as an alternative to angiotensin converting enzyme inhibition in patients with chronic systolic heart failure: rationale and design of the Aliskiren Trial to Minimize OutcomeS in Patients with HEart failuRE (ATMOSPHERE) study. Eur J Heart Fail 2011; 13: 107-114
2. McMurray JJ, Abraham WT, Dickstein K, Køber L, Massie BM, Krum H,. Aliskiren, ALTITUDE, and the implications for ATMOSPHERE. Eur J Heart Fail 2012; 14: 341-31:
3. Krum H, Massie B, Abraham WT, Dickstein K, Kober L, McMurray JJ,; ATMOSPHERE Investigators. Losing ALTITUDE? How should ASTRONAUT launch into ATMOSPHERE. Eur J Heart Fail 2013; 15: 1205-1207.
4. Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, Chaturvedi N, Persson F, Desai AS, Nicolaides M, Richard A, Xiang Z, Brunel P, Pfeffer MA,; ALTITUDE Investigators. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 2012; 367: 2204-2213.
5. Gheorghiade M, Böhm M, Greene SJ, Fonarow GC, Lewis EF, Zannad F, Solomon SD, Baschiera F, Botha J, Hua TA, Gimpelewicz CR, Jaumont X, Lesogor A, Maggioni AP,; ASTRONAUT Investigators and Coordinators. Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial. JAMA 2013; 309: 1125-1135
6. Maggioni AP, Greene SJ, Fonarow GC, Böhm M, Zannad F, Solomon SD, Lewis EF, Baschiera F, Hua TA, Gimpelewicz CR, Lesogor A, Gheorghiade M,; ASTRONAUT Investigators and Coordinators. Effect of aliskiren on post-discharge outcomes among diabetic and non-diabetic patients hospitalized for heart failure: insights from the ASTRONAUT trial. Eur Heart J 2013; 34: 3117-3127
7. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR,; PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014; 371: 993-1004.
8. Green CP, Porter CB, Bresnahan DR, Spertus JA,. Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart failure. J Am Coll Cardiol 2000; 35: 1245-1255.
9. Bretz F, Maurer W, Brannath W, Posch M,. A graphical approach to sequentially rejective multiple test procedures. Statist Med 2009; 28: 586-604.
10. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR,; PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014; 371: 993-1004.
11. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz M, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR,; PARADIGM-HF Committees Investigators. Baseline characteristics and treatment of patients in prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial (PARADIGM-HF). Eur J Heart Fail 2014; 16: 817-825.
12. Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B,; EMPHASIS-HF Study Group. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011; 364: 11-21.
13. McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Böhm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, Jaarsma T, Køber L, Lip GY, Maggioni AP, Parkhomenko A, Pieske BM, Popescu BA, Rønnevik PK, Rutten FH, Schwitter J, Seferovic P, Stepinska J, Trindade PT, Voors AA, Zannad F, Zeiher A,; Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Eur J Heart Fail 2012; 14: 803-869.
14. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJ, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Tang WH, Tsai EJ, Wilkoff BL,. 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2013; 128: 1810-1852.
15. Swedberg K, Komajda M, Böhm M, Borer JS, Ford I, Dubost-Brama A, Lerebours G, Tavazzi L,; SHIFT Investigators. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 2010; 376: 875-885.
16. MacDonald MR, Petrie MC, Hawkins NM, Petrie JR, Fisher M, McKelvie R, Aguilar D, Krum H, McMurray JJ,. Diabetes, left ventricular systolic dysfunction, and chronic heart failure. Eur Heart J 2008; 29: 1224-1240.